Know Cancer

or
forgot password

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line


Phase 1/Phase 2
18 Years
70 Years
Not Enrolling
Both
Multiple Myeloma

Thank you

Trial Information

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line


Inclusion Criteria:



- De novo multiple myeloma

- ECOG 0-2

- No serious co-morbid illnesses and adequate organ function

- > 4 weeks from systemic steroids

Exclusion Criteria:

- No existing secondary malignancies and no history of secondary malignancies in the
past 5 years

- No active autoimmune disease

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Multiple myeloma

Authority:

United States: Food and Drug Administration

Study ID:

K-0007

NCT ID:

NCT00116441

Start Date:

October 2000

Completion Date:

October 2004

Related Keywords:

  • Multiple Myeloma
  • Multiple Myeloma
  • Cancer
  • PSCT
  • Peripheral Stem Cell Transplant
  • Chemotherapy
  • GVAX
  • Multiple Myeloma
  • Neoplasms, Plasma Cell

Name

Location

Johns Hopkins UniversityBaltimore, Maryland  21205